Michael Tomsicek
Director/Board Member bij MILESTONE PHARMACEUTICALS INC.
Vermogen: 82 835 $ op 31-03-2024
Profiel
De heer Michael J. Tomsicek is een onafhankelijk niet-uitvoerend bestuurder bij Milestone Pharmaceuticals, Inc. en een CFO & Principal Accounting Officer bij CRISPR Therapeutics AG. Hij zetelt in de Raad van Bestuur van Milestone Pharmaceuticals, Inc. en Optimer Pharmaceuticals LLC. De heer Tomsicek was voorheen werkzaam als CFO, Treasurer, Principal Accounting Officer & VP bij ABIOMED, Inc., als Treasurer bij Cubist Pharmaceuticals, Inc., als CFO-Global Ultrasound Product Group bij General Electric Healthcare Technologies, Inc., als Manager-Commercial Finance & Business Planning bij Motorola Automotive & Industrial Electronics Group, en als Chief Financial Officer bij The Lexington. Hij was ook lid van de raad van bestuur van Trius Therapeutics, Inc. Hij behaalde zijn doctoraatsdiploma aan de Universiteit van Wisconsin en een MBA aan de Universiteit van Wisconsin.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
24-04-2023 | 7 830 ( 0.03% ) | 55 985 $ | 31-03-2024 | |
07-06-2023 | 15 000 ( 0.03% ) | 26 850 $ | 31-03-2024 |
Actieve functies van Michael Tomsicek
Bedrijven | Functie | Begin |
---|---|---|
MILESTONE PHARMACEUTICALS INC. | Director/Board Member | 01-04-2019 |
ACRIVON THERAPEUTICS, INC. | Director/Board Member | 01-10-2022 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Director/Board Member | 24-10-2013 |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Director/Board Member | 03-11-2022 |
Eerdere bekende functies van Michael Tomsicek
Bedrijven | Functie | Einde |
---|---|---|
CRISPR THERAPEUTICS AG | Director of Finance/CFO | 14-10-2021 |
ABIOMED, INC. | Director of Finance/CFO | 24-08-2017 |
CUBIST PHARMACEUTICALS INC | Director of Finance/CFO | 01-01-2015 |
General Electric Healthcare Technologies, Inc.
General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Corporate Officer/Principal | 01-09-2010 |
The Lexington
The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The private company is based in Ventura, CA. | Director of Finance/CFO | - |
Opleiding van Michael Tomsicek
University of Wisconsin | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MILESTONE PHARMACEUTICALS INC. | Health Technology |
CRISPR THERAPEUTICS AG | Health Technology |
Bedrijven in privébezit | 9 |
---|---|
ABIOMED, Inc.
ABIOMED, Inc. Medical SpecialtiesHealth Technology ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA. | Health Technology |
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
General Electric Healthcare Technologies, Inc.
General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Health Services |
The Lexington
The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The private company is based in Ventura, CA. | Health Services |
Motorola Automotive & Industrial Electronics Group | |
Acrivon Therapeutics, Inc. | |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Technology Services |